Ocean Biomedical (OCEAW) 10-Q2024 Q1 Quarterly report

Filed: 23 Dec 24, 7:50am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: Acquistion, carveout, composition, County, enhance, Entoro, facility, finder, fit, footnote, gain, hearing, influence, intrinsic, introduced, investee, investment, leak, likelihood, meaningful, merit, motion, opposition, penalty, posture, procedural, regularly, relief, respond, sought, Startup, subcontractor, Superior, Supreme, therewith, Topic, tranche, transparency, uncommon, underway

Removed: advanced, allegedly, coverage, defend, effected, pandemic, SPV, twelve, unamortized, vii, wrongdoing, wrongful

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

OCEAW similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002

I, Michelle Berrey, Chief Executive Officer of Ocean Biomedical, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

	(i)	The Quarterly Report on Form 10-Q of Ocean Biomedical, Inc. for the period ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, and

	(ii)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Dated: December 23, 2024

/s/ Michelle Berrey
Michelle Berrey
Chief Executive Officer
(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.